AC Immune SA(ACIU) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.56 | Insider Own | 38.53% | Shs Outstand | 91.1M | Perf Week | -9.64% |
| Market Cap | 0.23B | Forward P/E | 9.21 | EPS next Y | 147.77% | Insider Trans | -0.03% | Shs Float | 62.6M | Perf Month | -13.79% |
| Enterprise Value | 0.14B | PEG | - | EPS next Q | -0.18 | Inst Own | 24.21% | Short Float | 5.22% | Perf Quarter | -0.88% |
| Income | -0.05B | P/S | 10.34 | EPS this Y | 39.46% | Inst Trans | -1.63% | Short Ratio | 16.83 | Perf Half Y | -25.74% |
| Sales | 0.02B | P/B | 4.7 | EPS next 5Y | - | ROA | -25.54% | Short Interest | 3.26M | Perf YTD | -28.34% |
| Book/sh | 0.48 | P/C | 2.45 | EPS past 3/5Y | 1.71% 1.71% | ROE | -79.01% | 52W High | -43.75% ($4.00) | Perf Year | -37.33% |
| Cash/sh | 0.92 | P/FCF | - | Sales past 3/5Y | 1.45% -23.52% | ROIC | -113.99% | 52W Low | 7.4% ($2.10) | Perf 3Y | -16.97% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 4.48% | Gross Margin | - | Volatility(W/M) | 6.11% 5% | Perf 5Y | -64.73% |
| Dividend TTM | - | EV/Sales | 6.35 | Sales Y/Y TTM | -33.68% | Oper. Margin | -249.4% | ATR (14) | 0.13 | Perf 10Y | -84.91% |
| Dividend Ex-Date | - | Quick Ratio | 0.93 | EPS Q/Q | 110.21% | Profit Margin | -245.27% | RSI (14) | 34.49 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.93 | Sales Q/Q | 1110.62% | SMA20 | -9.95% ($2.5) | Beta | 1.63 | Target Price | $8.56 |
| Payout | - | Debt/Eq | 0.12 | Earnings | 2026/8/5 | SMA50 | -14.45% ($2.63) | Rel Volume | 2.42 | Prev Close | $2.31 |
| Employees | 122 | LT Debt/Eq | 0.09 | EPS/Sales Surpr. | 121.61% 98.88% | SMA200 | -18.06% ($2.75) | Avg Volume(3M) | 0.19M | Price | $2.25 |
| IPO | 2016/9/23 | Option/Short | Yes/Yes | Trades | 1312 | Volume | 469,029 | Change | -2.6% |
A clinical-stage biotech company targeting neurodegenerative diseases such as Alzheimer's and Parkinson's. Headquartered in Switzerland, the company leverages its two proprietary technology platforms, SupraAntigen and Morphomer, to develop a broad pipeline of active immunotherapies and diagnostic candidates, positioning itself as a leader in precision prevention.
Over the past 1 year, on the lower side
44% below its 1-year high.
Traded more than usual. That is 242% of its average volume.
ACIU has weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +39.5% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,034. Peers typically go for $1,034.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -64.7%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 24.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #287 of 594 in the industry
Based on market cap of $229M.
FAQ
What kind of company is ACIU?
ACIU belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ACIU?
The market cap of ACIU is approximately $229M, ranking 3,912 within its sector.
What is the 52-week high and low for ACIU?
ACIU has recorded a 52-week high of $4.00 and a low of $2.10.
